Semax

FDA status

Not an FDA-approved drug for any indication, and not in active development toward approval. That says nothing about whether it is sold — it is.

503A compounding

Absent from Categories 1, 2 and 3 in the list updated 2026-05-14 — verified by fetching and text-extracting the document directly. Category 2 contains exactly six substances (Cesium Chloride, Domperidone, Germanium Sesquioxide, Ibutamoren Mesylate, Kisspeptin-10, Quinacrine HCl for intrauterine administration) and semax is not among them. The two nominations — Wells Pharmacy Network (FDA-2015-N-3534-0284) and LDT Health Solutions (FDA-2018-N-2973-0002) — were WITHDRAWN by the nominators (withdrawal document IDs FDA-2015-N-3534-0484 and -0485). Withdrawal is not a legalisation event: semax did not enter Category 1, is not on the 503A bulks list, and remains non-compoundable. Note the unusual wrinkle — FDA continued evaluating semax 'at its discretion' AFTER the nominations were withdrawn, on its own initiative, and is taking it to PCAC anyway.

Evidence

Administration check run and PASSED — this is NOT an endogenous-biomarker artefact. Semax really was given to humans (intranasally; FDA found no literature at all for the subcutaneous route), and semax is a registered drug in Russia sold as 0.1% and 1% nasal drops. The tier is nevertheless assigned on design, not on exposure counts or on foreign registration. No human RCT is verifiable. The two human studies FDA actually evaluated were: (1) Cherkasova et al. 2002, a meeting abstract with no full published article locatable, in an unknown number of subjects with chronic ischemic brain disease, which did not discuss clinical function before or after; and (2) Koroleva et al. 1996 (Bull Exp Biol Med 122:1107-1109, doi:10.1007/BF02447659), open-label, no blinding, no control group, n=12 migraine and n=25 trigeminal neuralgia. Hold the two apart rather than averaging them: Koroleva is the one FDA describes as open-label and uncontrolled, and it is the only one whose sample size FDA gives. For Cherkasova, FDA reports NO design information at all — not a control arm, not blinding, not an N — so this record does not characterise its design either way, and an unknown number of subjects cannot be called small. Note also what the Cherkasova finding is and is not: FDA says the authors 'do not provide full results for these lab values, nor do they discuss clinical function before and after receiving semax'. That is a reporting gap, not a reported null result, and this record will not upgrade one into the other. The precise statement is: no human RCTs; the only human study whose design FDA describes was open-label and uncontrolled, and what the two references reported, FDA characterised as demonstrating lack of effectiveness. ON THE TIER, DELIBERATELY AND NOT BY DEFAULT: 'animal-or-in-vitro-only' is the enum's label for 'no human RCTs', which is exactly true here, and the explainer that renders beside the badge says so. The badge WORD understates the human record, and that is a real cost, but the alternative is worse in the direction that matters: 'promising-but-unproven' would render the word 'Promising' over a compound whose two evaluated references FDA said demonstrated LACK of effectiveness, and 'no-credible-evidence' would deny the animal literature FDA discusses at length. The closed enum has no tier for 'human data exists and it pointed the wrong way', so the tier is held at the one that is literally true and the precision is carried here rather than flattering the compound in a badge. If a tier is ever added for that case, this record is the one to move first. IMPORTANT GAP, STATED RATHER THAN PAPERED OVER: a Russian-language clinical literature on semax in stroke does exist and is real — e.g. Gusev et al. 2018 (Zh Nevrol Psikhiatr Im S S Korsakova 118(3.Vyp.2):61-68, doi:10.17116/jnevro20181183261-68), Gusev et al. 2005, Gusev et al. 1997, Shmyrev et al. 1998. We have NOT read these in full and therefore do not assert what they administered, what design they used, or what they found. FDA did not consider them either, but for a procedural reason rather than a scientific one — 21 CFR 10.20(c)(2) requires a verified English translation, and none was submitted. Vendor pages citing 'Gusev' as proof of a positive controlled stroke trial are citing a paper neither they nor we have verified.

What FDA found

FDA’s own words. These are the most citable thing on this site, and the least likely to appear anywhere funded by someone selling the compound.

• FDA staff propose not adding semax (free base) or semax acetate to the 503A Bulks List, ahead of the Pharmacy Compounding Advisory Committee meeting on 23-24 July 2026.

  A staff proposal is not a final determination. The briefing document states: 'The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized.'

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “Accordingly, we propose not adding semax (free base) or semax acetate to the 503A Bulks List.”

  Checked against the source on 16 July 2026.

• FDA concluded there is insufficient evidence of effectiveness to support the use of semax-related bulk drug substances as a treatment for cerebral ischemia, migraine and trigeminal neuralgia.

  Those three indications are the whole evaluation, and none of them is what semax is sold for in the US. FDA declined to evaluate ADHD because 'supporting literature for this use was not found', and declined 'nootropic' as a standalone use because it has no ICD-10 code and no professional society treatment guidelines — folding it into cerebral ischemia instead. Separately, and regardless of which uses were evaluated: semax is not on the 503A bulks list, so it may not lawfully be used in 503A compounding for ANY use. That follows from its absence from the list itself, not from the scope of FDA's evaluation. The nootropic and ADHD markets rest on an evidentiary vacuum FDA could not find literature to fill, which cuts against those claims rather than leaving room for them.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “We have insufficient evidence of effectiveness to support the use of semax-related BDSs as a treatment for cerebral ischemia, migraine and trigeminal neuralgia.”

  Checked against the source on 16 July 2026.

• The only reference FDA evaluated in cerebral ischemia (Cherkasova et al. 2002) is a professional society meeting abstract for which no full published article could be located. It reports an unknown number of human subjects with chronic ischemic brain disease who received intranasal semax, and FDA states the authors did not provide full results for the lab values they measured and did not discuss clinical function before and after receiving semax.

  Recorded because this reference does double duty in FDA's document and the two jobs pull in opposite directions — it is one of only two references in the effectiveness evaluation, AND it is the sole basis for the bleeding-risk flag. Both loads rest on an abstract whose full article nobody, FDA included, could find. Note precisely what FDA does and does not say about its design: FDA gives no sample size, no control arm, no blinding, and no design detail of any kind. It cannot be called small, and it cannot be called uncontrolled — the information to say either does not exist. FDA also notes the authors 'do not specify if these labs were done in the animal or human subjects', because the abstract describes a study in which semax was given to both rats and humans. 'Do not discuss clinical function' is an absence of reporting, not a reported finding of no effect; the distinction is the difference between a study that looked and found nothing and a study that never said.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “This reference was submitted by the nominators and is an abstract from a professional society meeting. No full published article could be located for this reference. ... An unknown number of human subjects with chronic ischemic brain disease received intranasal semax ... Although the authors measured labs related to blood clotting (such as plasmin, antithrombin III, and protein C), the authors do not provide full results for these lab values, nor do they discuss clinical function before and after receiving semax.”

  Checked against the source on 16 July 2026.

• In the only study FDA evaluated in trigeminal neuralgia (Koroleva et al. 1996, n=25 total, single intranasal dose, open-label and uncontrolled), FDA concluded that semax was not effective in resolving pain for the majority of subjects. In the 16 subjects with typical trigeminal neuralgia the authors reported no changes in pain characteristics, sensation or pain thresholds, and concluded that semax does not exhibit analgesic activity by itself.

  Recorded because this is a negative finding from the nominator's OWN submitted reference — the nominators submitted a study whose authors concluded the drug did not work. The study split three ways, and the positive-looking arms are reported here in full rather than filtered. Trigeminal neuralgia (n=25) divided into 16 subjects with typical trigeminal neuralgia and 9 with dental plexalgia; in the dental plexalgia subgroup FDA reports that 'pain resolved in 6 subjects and 3 subjects reported a decrease in pain severity'. FDA immediately qualifies that: 'MPST results showed that overall, there was no reduction in frequency of pain attacks, duration of pain attacks, and differences in sensory characteristics of pain', and 'it appears that the authors assigned arbitrary units when they discussed their findings'. In the migraine arm (n=12), FDA notes 4 of 12 subjects (33%) reported cessation of headache pain, and concluded that 'semax was not effective in resolving headache pain for the majority of subjects with migraine'. FDA's listed limitations: small sample size, no blinding, no control group, no reporting of actual scores or standard deviations, and insufficient detail on design and conduct.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “no significant changes in TSEP were observed after a single intranasal administration of semax. This observation indicates that semax does not exhibit analgesic activity by itself.”

  Checked against the source on 16 July 2026.

• FDA identified no pharmacokinetic studies in humans following exposure to semax (free base) or semax acetate via any route of administration, and no safety data at all for the subcutaneous route proposed in the nominations.

  The route mismatch is the practical point. Every human reference FDA found used INTRANASAL semax. Semax is nonetheless marketed in the US as an injectable — FDA's own briefing document cites vendor and clinic pages selling it. The human exposure history that vendors invoke does not cover the route those same vendors sell.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “We were not able to find pharmacokinetic studies in humans following exposure to semax (free base) or semax acetate via any ROA. There are no safety data for semax (free base) and semax acetate administered by the proposed SC ROA.”

  Checked against the source on 16 July 2026.

• FDA found that semax injection and intranasal products are widely marketed in the United States through health/wellness clinics, medical concierge services, functional and regenerative medicine clinics, and online retailers, for a list of conditions including anxiety, depression, ADHD, stroke, ALS, Parkinson's disease and Alzheimer's disease.

  None of those marketed uses is supported by the evaluation. FDA evaluated three indications and found the evidence insufficient for all three; the Alzheimer's, ALS and Parkinson's claims were not supported by literature FDA could locate at all. FDA also notes it is unclear to what extent semax has actually been used in compounding.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026Checked against the source on 16 July 2026.

• FDA states there is no United States Pharmacopeia or National Formulary drug substance monograph for semax (free base) or semax acetate, and that neither is a component of an FDA-approved drug.

  This single sentence closes all three doors at once, which is why it is recorded verbatim rather than paraphrased. Section 503A permits compounding with a bulk drug substance only if it (a) has an applicable USP or NF monograph, (b) is a component of an FDA-approved drug, or (c) appears on the 503A bulks list. FDA says here that semax fails (a) and (b); the list itself establishes it fails (c). 'Not FDA-approved' understates it — semax is not an ingredient of any approved product either, so there is no approved article anywhere in the US drug supply from which to argue a lineage.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “There is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for semax (free base) or semax acetate, and neither is a component of an FDA-approved drug.”

  Checked against the source on 16 July 2026.

• FDA concluded that both semax (free base) and semax acetate are not well-characterized from the physical and chemical characterization perspective, citing inconsistent naming conventions and missing quality-control data on impurities, aggregates, bacterial endotoxins and microbial bioburden.

  FDA reached the same not-well-characterized conclusion separately for each of the two substances, in parallel subsections. The naming half of it is a documented patient-safety argument rather than pedantry: FDA states that it 'has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name', and that inconsistent naming 'represent[s] a safety risk for patients as they may be dosed with a different BDS than the physician ordered'. Semax is a common name, not a United States Adopted Name. FDA also notes that none of the US vendor websites it searched indicates whether the marketed product contains the free base, a salt, or an ester.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “Semax acetate is considered not well-characterized from the physical and chemical characterization perspective because (1) inconsistent naming conventions that do not follow established chemical nomenclature standards (e.g., INN, IUPAC, USAN), and (2) certain critical characterization data specific to semax acetate (including impurities, aggregates, microbial bioburden and/or bacterial endotoxin) were not found in the publicly available scientific literature, and the CoAs provided, which were offered as evidence to establishing identity, purity, and impurity profiles of the substance, lacked specific tests (including impurities, aggregates, microbial and bacterial endotoxins).”

  Checked against the source on 16 July 2026.

• FDA's overall effectiveness conclusion is not merely that evidence is absent: FDA stated that only two usable references existed, that both lacked sufficient detail on design and conduct, and that the available references demonstrated lack of effectiveness.

  Note the distinction this record refuses to blur, because it cuts both ways. 'Insufficient evidence of effectiveness' and 'demonstrated lack of effectiveness' are different findings, and FDA made BOTH about semax in the same document — the first as the formal standard it applies, the second as a description of what the two studies actually reported. For most compounds in this library the honest statement is only the first. For semax it is both, which is a stronger negative than 'no data'. Against that, the counterweight is stated rather than buried: only two references reached FDA's evaluation at all, so 'demonstrated lack of effectiveness' describes two small uncontrolled studies, not a body of literature.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “Only two available references were available with insufficient details on the design and conduct of the studies, and the available references demonstrated lack of effectiveness and were limited by small sample size and lack of information about some relevant clinical endpoints.”

  Checked against the source on 16 July 2026.

• FDA found no evidence that semax has actually been used in pharmacy compounding: no outsourcing facility has reported compounding semax-containing products since 2019, a search identified no pharmacies marketing them, the nominators submitted 38 articles of which none discussed a compounded semax formulation, and no studies were found in which semax was used as a compounded drug product.

  Historical use in compounding is one of the four criteria FDA balances, and semax scores close to zero on it. The finding matters mainly because of what it implies about the US supply: FDA simultaneously found semax injection and nasal products 'widely marketed' through clinics and online retailers, while finding essentially no evidence of lawful compounding behind them. FDA does record one enforcement data point, citing a press release from the US Attorney for the Eastern District of Kentucky stating that a pharmacy compounded and distributed products containing semax between October 2018 and April 2020; FDA adds that it is unclear which form of semax was used. We have not read the underlying press release and do not characterise the charges beyond what FDA's document says.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “No outsourcing facility has reported compounding drug products containing semax since 2019. ... A Google search did not identify any pharmacies that market drug products containing any form of semax. ... No studies were found in which semax was used as a compounded drug product.”

  Checked against the source on 16 July 2026.

Documented safety signals

• FDA concluded there is insufficient clinical information to characterize the safety profile of semax (free base) or semax acetate, and that use of semax-related bulk drug substances in compounding may raise safety concerns.

  Read this against the exposure count rather than instead of it. Several hundred documented human exposures coexist with an uncharacterised safety profile, because most of the references simply did not discuss safety: FDA notes one reference reported no adverse events (Koroleva et al. 1996) and the remainder did not discuss adverse events at all. Three of the references are meeting abstracts whose full studies were unavailable — including all of the paediatric data. Absence of reported harm in studies that never looked for harm is not a safety finding.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “There is insufficient clinical information to characterize the safety profile of semax (free base) or semax acetate.”

  Checked against the source on 16 July 2026.

• FDA flagged a possible bleeding risk: one reference discussed possible anti-thrombotic properties of semax, raising concern particularly for populations at risk for bleeding or for people taking other medications that increase bleeding risk.

  The labeling half of that quote is the part that carries the weight. FDA's objection is not only that a bleeding signal exists but that compounded drugs 'do not include labeling that would adequately warn physicians and patients of such risks' — so the warning that would let someone on an anticoagulant avoid the interaction is structurally absent from the product. Note also the thinness of the underlying signal: it rests on a single reference (Cherkasova et al. 2002), which is itself the meeting abstract whose full article we could not locate. A possible risk flagged from an unverifiable abstract is not a quantified risk, and it is not reassurance either.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “One reference (Cherkasova et al. 2002) discussed possible anti-thrombotic properties of semax and this raises concern about the risk of bleeding, particularly in certain populations at risk for bleeding or if combined with other medications that increase bleeding risk. Compounded drugs do not include labeling that would adequately warn physicians and patients of such risks.”

  Checked against the source on 16 July 2026.

• FDA identified no clinical studies assessing immunogenicity or aggregation of semax (free base) or semax acetate, and concluded available information is insufficient to conclude that the substances do not present these risks.

  FDA's concern is specific to the injection route proposed in the nominations, on the basis that peptides have an inherent tendency to aggregate and that aggregation is a risk factor for immunogenicity. FDA notes peptides with as few as two amino acids have been shown to aggregate, so semax's small size (seven amino acids) is not a defence.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026Checked against the source on 16 July 2026.

• FDA identified quality and manufacturing gaps in the withdrawn nominations: no information on the nature of individual impurities permitted at up to 1.0% and 2.0% levels, no water solubility data, no microbial bioburden testing result, and a lack of endotoxin data for injectable routes of administration.

  Sourced from FDA's review of the certificates of analysis the two withdrawn nominators supplied — i.e. the best documentation the nominating side chose to put forward. FDA states the impurity information 'also cannot be found from publicly available' sources. FDA also found no information on how an appropriate container and pump for an intranasal spray product would be selected and qualified.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026Checked against the source on 16 July 2026.

• FDA's search of the FAERS adverse event database through 3 December 2025 retrieved one report (#25343150): a consumer reported ocular pain and eye burning after using semax 0.1% nasal drops purchased online, reported hospitalization following the exposure, and reported that the eye pain had not resolved a year later.

  One report is one report, and it is worth stating precisely what it is and is not. It is a direct consumer report, not an investigated case: FDA does not adjudicate causation, the product was bought online rather than dispensed, and its actual contents were never verified. FAERS is a passive system and cannot support a rate. What makes it worth recording is the structural point FDA attaches in a footnote — compounders under section 503A generally do not report adverse events to FDA, so 'unless an adverse event report is submitted to FDA, the Agency may not be aware of adverse events associated with a product compounded under section 503A'. A near-empty FAERS record for a widely marketed compound is evidence about the reporting system, not evidence about the compound. FDA's two literature searches identified no published case reports of adverse events in humans.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026Checked against the source on 16 July 2026.

• FDA identified no acute toxicity, repeat-dose toxicity, genotoxicity, or developmental and reproductive toxicity studies of semax, and no adequate carcinogenicity assessment.

  This is the nonclinical floor, and semax is below it on every rung: FDA records separately, for each study type, that 'the nominator did not submit, and FDA did not identify' such studies. The single carcinogenicity-adjacent study FDA found (Meshavkin et al. 2013, in tumour-bearing female mice) FDA judged 'not adequately designed to assess the carcinogenic potential of semax', noting it tested one fixed level, used only females, and ran under three months against a standard of two years. Read this next to the exposure history rather than instead of it: several hundred people have received semax without the animal toxicology package that would normally precede a first-in-human study existing at all.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026Checked against the source on 16 July 2026.

• FDA flagged an unassessed abuse potential: in mice, semax potentiated amphetamine-induced dopamine release in the striatum, which FDA called concerning because increased dopaminergic tone in the striatum is a response typically induced by drugs of abuse such as cocaine, and FDA identified no studies informing whether semax has reinforcing or addictive properties.

  Recorded because it inverts the marketing. Semax is sold in the US partly for opioid withdrawal — FDA's own survey of vendor sites lists that use — and the one nonclinical signal FDA singled out as concerning points toward abuse liability rather than away from it. Hold the strength of the claim steady in both directions: this is a mouse finding about a drug interaction, FDA did not conclude that semax is abusable, and the honest statement is that the question was never studied. FDA carried the point up into its formal conclusion section, so it is not an aside in the text.

  Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

  “This finding is concerning because increased dopaminergic tone in the striatum is a response typically induced by drugs of abuse such as cocaine ... At the time of this evaluation, the nominator did not submit, and FDA did not identify nonclinical studies to demonstrate whether semax has reinforcing and addictive properties to inform its abuse potential.”

  Checked against the source on 16 July 2026.

Questions people actually ask

Every answer cites the document behind it. Where the honest answer is “nobody knows”, that is the answer you will get.

Is Semax legal in the US in 2026?

No. Semax appears in none of the three categories of FDA's 503A bulk drug substances list as updated 14 May 2026 — it is not on the list at all — so semax may not lawfully be used to compound a drug under section 503A of the Federal Food, Drug, and Cosmetic Act, for any indication and regardless of whether a prescriber writes for it. Absence from the list is the restriction itself, not a technicality that a prescription cures. Being off the list is a statement about the compounding pathway; what any individual state or federal enforcement action treats as a crime is a separate question this answer does not address.

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026Checked against the source on 16 July 2026.

Did Semax become legal when the FDA nominations for it were withdrawn?

No. The two nominations to add semax to FDA's 503A bulks list were withdrawn by the nominators themselves, and a withdrawn nomination does not place a substance on the list — it removes the request, not the restriction. Semax's status moved sideways rather than toward legality: it never entered Category 1, it is absent from the 503A bulks list entirely, and it therefore remains outside lawful compounding under section 503A. FDA states that it is evaluating semax acetate and semax (free base) at its own discretion despite the withdrawals, and FDA staff went on to propose not adding either substance.

Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

“The nominations were withdrawn and FDA is evaluating the substances at its discretion.”

Checked against the source on 16 July 2026.

Did FDA approve Semax?

No. FDA has never approved semax, and FDA states that neither semax (free base) nor semax acetate is even a component of an FDA-approved drug, and that no United States Pharmacopeia or National Formulary drug substance monograph exists for either. Semax is a registered drug in Russia, sold there as 0.1% and 1% nasal drops, but a foreign registration is not an FDA approval and confers no United States legal status.

Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

“There is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for semax (free base) or semax acetate, and neither is a component of an FDA-approved drug. ... Semax is a registered drug in Russia and is available as 0.1% and 1% nasal drops.”

Checked against the source on 16 July 2026.

Is there any human evidence that Semax works?

No randomised controlled trial of semax in humans is verifiable in the English-language literature. FDA evaluated semax for cerebral ischemia, migraine and trigeminal neuralgia and found only two usable human references: a 2002 meeting abstract with no locatable full article, in an unknown number of subjects, which did not discuss clinical function before or after — a gap in what was reported, not a reported finding of no effect — and a 1996 study with no blinding and no control group. FDA concluded both that the evidence of effectiveness is insufficient for all three conditions and that the available references demonstrated lack of effectiveness. Professional society treatment guidelines for all three conditions do not discuss semax. Semax has been administered to several hundred people, but exposure is not efficacy. A Russian-language clinical literature on semax in stroke does exist; FDA did not consider it, because 21 CFR 10.20(c)(2) requires a verified English translation and none was submitted.

Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

“Only two available references were available with insufficient details on the design and conduct of the studies, and the available references demonstrated lack of effectiveness and were limited by small sample size and lack of information about some relevant clinical endpoints.”

Checked against the source on 16 July 2026.

Does Semax work as a nootropic or for ADHD?

FDA evaluated neither use for semax, and said why in each case. FDA declined to evaluate semax for ADHD because supporting literature for that use was not found. FDA declined to treat 'nootropic' as a standalone use because it has no ICD-10 code and no professional society treatment guidelines could be found for it, folding it instead into the evaluation of cerebral ischemia — for which FDA concluded the evidence of effectiveness is insufficient. No human trial supporting a cognitive-enhancement claim for semax was identified anywhere in FDA's review, and semax may not lawfully be compounded in the US for these or any other uses, because it is not on FDA's 503A bulks list.

Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

“Semax was also nominated for “ADHD” and “nootropic”. ADHD was not evaluated because supporting literature for this use was not found. “Nootropic” does not have an ICD-10 code and no professional society treatment guidelines could be found for this use.”

Checked against the source on 16 July 2026.

Can I get Semax from a compounding pharmacy?

Not lawfully. Semax is not on FDA's 503A bulks list, has no USP or NF monograph, and is not a component of an FDA-approved drug, so no US pharmacy may lawfully compound it under section 503A. FDA also found little sign that lawful compounding is where the US supply comes from: no outsourcing facility has reported compounding semax-containing products since 2019, and FDA's own search identified no pharmacies marketing them. FDA nonetheless found semax injection and intranasal products widely marketed in the United States through health and wellness clinics, medical concierge services, functional and regenerative medicine clinics, and online retailers.

Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

“No outsourcing facility has reported compounding drug products containing semax since 2019. ... A Google search did not identify any pharmacies that market drug products containing any form of semax.”

Checked against the source on 16 July 2026.

Is Semax safe?

Nobody knows, including FDA, which concluded that there is insufficient clinical information to characterize the safety profile of semax (free base) or semax acetate, and that use of semax-related bulk drug substances in compounding may raise safety concerns. That is not a finding of safety and not a finding of harm — it is a finding that the data needed to answer the question does not exist. FDA identified no human pharmacokinetic study by any route, no safety data at all for the subcutaneous injection route that US vendors sell, no acute toxicity, repeat-dose toxicity, genotoxicity or developmental and reproductive toxicity studies, and no clinical studies of immunogenicity. FDA flagged a possible bleeding risk, on a thin basis it states plainly: one reference (Cherkasova et al. 2002) discussed possible anti-thrombotic properties of semax, and FDA writes that the direct evidence of anticoagulant and antithrombotic properties comes from studies in non-ischemic rats. That reference is itself the meeting abstract whose full article could not be located. FDA notes compounded drugs carry no labeling that would warn physicians and patients of such a risk — so someone taking an anticoagulant gets no warning either way. Several hundred people have received semax, but most of the studies never looked for adverse events, and absence of reported harm in studies that did not look is not a safety finding.

Semax-Related Bulk Drug Substances — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — FDA, 23 July 2026

“There is insufficient clinical information to characterize the safety profile of semax (free base) or semax acetate. ... One reference (Cherkasova et al. 2002) discussed possible anti-thrombotic properties of semax and this raises concern about the risk of bleeding, particularly in certain populations at risk for bleeding or if combined with other medications that increase bleeding risk. ... Direct evidence that semax has anticoagulant and antithrombotic properties has been provided by studies conducted in non-ischemic rats.”

Checked against the source on 16 July 2026.